X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Among 222 'novel therapeutics' approved by the FDA from 2001 through 2010, 32 percent were affected by a postmarket safety event. (Photo: iStock)

Nearly a third of all drugs approved in the last decade by the U.S. Food and Drug Administration subsequently had “postmarket safety events,” which included boxed warnings, safety communications and/or withdrawal of the products, according to a study by researchers at the Yale School of Medicine published on the American Medical Association’s JAMA Network.

Katie Kuehner-Hebert

Katie Kuehner-Hebert is a freelance writer based in Running Springs, Calif. She has more than three decades of journalism experience, with particular expertise in employee benefits and other human resource topics.

More from this author

BenefitsPRO Broker Expo 2020Event

The premier educational and networking event for employee benefits brokers and agents.

Get More Information
 

BenefitsPRO

Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2019 ALM Media Properties, LLC. All Rights Reserved.